3,953 Shares in Boston Scientific Co. (NYSE:BSX) Purchased by Sanibel Captiva Trust Company Inc.

Sanibel Captiva Trust Company Inc. acquired a new stake in Boston Scientific Co. (NYSE:BSX - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 3,953 shares of the medical equipment provider's stock, valued at approximately $399,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Covenant Asset Management LLC bought a new position in Boston Scientific in the fourth quarter valued at approximately $3,405,000. Bank Pictet & Cie Europe AG boosted its stake in Boston Scientific by 40.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after acquiring an additional 21,173 shares during the last quarter. Kentucky Retirement Systems Insurance Trust Fund boosted its stake in Boston Scientific by 8.4% in the fourth quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 47,284 shares of the medical equipment provider's stock valued at $4,223,000 after acquiring an additional 3,683 shares during the last quarter. Entropy Technologies LP bought a new position in Boston Scientific in the fourth quarter valued at approximately $214,000. Finally, Portfolio Design Labs LLC bought a new position in Boston Scientific in the fourth quarter valued at approximately $975,000. 89.07% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

BSX has been the topic of several analyst reports. Evercore ISI increased their target price on shares of Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. BTIG Research reiterated a "buy" rating and issued a $124.00 target price on shares of Boston Scientific in a report on Wednesday, April 23rd. Citigroup reiterated a "buy" rating and issued a $125.00 target price (up from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Barclays increased their target price on shares of Boston Scientific from $118.00 to $125.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Finally, Wall Street Zen upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Twenty-one research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Boston Scientific currently has an average rating of "Buy" and an average target price of $116.00.

Insider Buying and Selling at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,314 shares of the business's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the transaction, the executive vice president now directly owns 22,235 shares in the company, valued at $2,269,304.10. The trade was a 43.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Vance R. Brown sold 4,826 shares of the business's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the transaction, the senior vice president now owns 36,193 shares in the company, valued at $3,441,592.37. This represents a 11.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 411,970 shares of company stock worth $42,406,693. Insiders own 0.50% of the company's stock.

Boston Scientific Stock Up 1.1%

BSX stock traded up $1.04 during midday trading on Friday, hitting $99.60. The company's stock had a trading volume of 10,330,779 shares, compared to its average volume of 6,562,299. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. Boston Scientific Co. has a twelve month low of $71.88 and a twelve month high of $107.17. The company's fifty day moving average price is $101.03 and its 200 day moving average price is $98.68. The stock has a market capitalization of $147.35 billion, a P/E ratio of 79.68, a PEG ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The firm had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. During the same period in the previous year, the business earned $0.56 EPS. The company's revenue was up 20.9% compared to the same quarter last year. As a group, equities research analysts predict that Boston Scientific Co. will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.